NeuroPace, Inc. – Trademark Portfolio
Entity Type: 03
NeuroPace, Inc. holds 16 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 12 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 3 trademarks are registered and 1 is pending. Notable registered marks include RNS and NEUROPACE. The owner is based in Mountain View, CA.
455 N. Bernardo Avenue
Mountain View, CA 94043
Showing of trademarks Trademarks
Trademark Classifications
NeuroPace, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does NeuroPace, Inc. have?
NeuroPace, Inc. has 16 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 pending, 10 abandoned, 2 cancelled.
What trademark classes does NeuroPace, Inc. file in?
NeuroPace, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 9 (Computers & Electronics). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are NeuroPace, Inc.'s most well-known trademarks?
NeuroPace, Inc.'s registered trademark portfolio includes well-known marks such as RNS and NEUROPACE. These are among 3 currently registered trademarks in the portfolio.
What is NeuroPace, Inc.'s trademark registration success rate?
NeuroPace, Inc. has a 20% trademark registration rate, with 3 out of 15 resolved applications resulting in successful registration. Currently, 1 application is pending review.